Anticoagulation Treatment Clinical Trial
— NOACOfficial title:
Prospective Register Study to Record Safety and Efficacy of New Oral Anticoagulants
| NCT number | NCT01588119 |
| Other study ID # | NOAC |
| Secondary ID | |
| Status | Recruiting |
| Phase | |
| First received | |
| Last updated | |
| Start date | November 2011 |
| Est. completion date | December 2024 |
Patients, who are adjusted to a new oral anticoagulant (Dabigatran, Rivaroxaban, Apixaban, Edoxaban) in routine treatment will recorded in this register. Within this register a characterization of patients (with regard to demography and indication) and therapy (with regard to medication, dose and duration) will be done. On basis of defined clinical relevant end points the long-term efficacy and safety will be evaluated.
| Status | Recruiting |
| Enrollment | 5000 |
| Est. completion date | December 2024 |
| Est. primary completion date | December 2024 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - indication for treatment with long term anticoagulation - initial adjustment or change to nex oral anticoagulant within routine treatment - indication for treatment with long term anticoagulation within the register: - permanent anticoagulation in arterial fibrillation - intended anticoagulation in acute venous thromboembolism for min. 3 months - other anticoagulation for min. 3 months within the approved indication Exclusion Criteria: - missing Informed Consent Form - missing phone number for telephone follow up - contraindication for therapy with new oral anticoagulant (Dabigatran, Rivaroxaban, Apixaban, Edoxaban) according to Summary of Product Characteristics |
| Country | Name | City | State |
|---|---|---|---|
| Germany | Universitätsklinikum Dresden on behalf of GWT-TUD GmbH | Dresden |
| Lead Sponsor | Collaborator |
|---|---|
| GWT-TUD GmbH |
Germany,